Ser1061
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1061  -  STAG2 (human)

Site Information
DDtMsVIsGIssrGS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452863

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 )
Disease tissue studied:
breast cancer ( 5 , 6 , 11 , 12 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 5 ) , cervical cancer ( 23 ) , cervical adenocarcinoma ( 23 ) , leukemia ( 27 , 28 ) , chronic myelogenous leukemia ( 27 , 28 ) , lung cancer ( 3 , 12 ) , non-small cell lung cancer ( 12 ) , non-small cell lung adenocarcinoma ( 3 ) , lymphoma ( 7 ) , Burkitt's lymphoma ( 7 ) , ovarian cancer ( 5 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 20 ) , 293 (epithelial) [AT1 (human), transfection] ( 19 ) , 293E (epithelial) ( 16 ) , A549 (pulmonary) ( 8 ) , BJAB (B lymphocyte) ( 7 ) , breast ( 1 , 5 ) , BT-20 (breast cell) ( 12 ) , BT-549 (breast cell) ( 12 ) , Calu 6 (pulmonary) ( 12 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 13 ) , Flp-In T-Rex-293 (epithelial) ( 13 ) , GM00130 (B lymphocyte) ( 21 ) , H2009 (pulmonary) ( 12 ) , H2077 (pulmonary) ( 12 ) , H2887 (pulmonary) ( 12 ) , H322M (pulmonary) ( 12 ) , HCC1359 (pulmonary) ( 12 ) , HCC1937 (breast cell) ( 12 ) , HCC2279 (pulmonary) ( 12 ) , HCC366 (pulmonary) ( 12 ) , HCC4006 (pulmonary) ( 12 ) , HCC78 (pulmonary) ( 12 ) , HCC827 (pulmonary) ( 12 ) , HeLa (cervical) ( 4 , 18 , 26 , 29 , 31 ) , HeLa S3 (cervical) ( 23 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 6 ) , HMLER ('stem, breast cancer') ( 6 ) , HOP62 (pulmonary) ( 12 ) , HUES-7 ('stem, embryonic') ( 24 ) , HUES-9 ('stem, embryonic') ( 17 ) , Jurkat (T lymphocyte) ( 9 , 15 , 22 , 25 , 30 ) , K562 (erythroid) ( 10 , 27 , 28 ) , LCLC-103H (pulmonary) ( 12 ) , LOU-NH91 (squamous) ( 12 ) , MCF-7 (breast cell) ( 12 ) , MDA-MB-231 (breast cell) ( 12 ) , MDA-MB-468 (breast cell) ( 12 ) , NCI-H1395 (pulmonary) ( 12 ) , NCI-H1568 (pulmonary) ( 12 ) , NCI-H157 (pulmonary) ( 12 ) , NCI-H1648 (pulmonary) ( 12 ) , NCI-H1666 (pulmonary) ( 12 ) , NCI-H2030 (pulmonary) ( 12 ) , NCI-H2172 (pulmonary) ( 12 ) , NCI-H322 (pulmonary) ( 12 ) , NCI-H460 (pulmonary) ( 12 ) , NCI-H520 (squamous) ( 12 ) , NCI-H647 (pulmonary) ( 12 ) , ovary ( 5 ) , PC9 (pulmonary) ( 3 , 12 ) , SKBr3 (breast cell) ( 11 )

Upstream Regulation
Treatments:
nocodazole ( 23 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

4

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

5

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

6

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

7

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

8

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

9

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

10

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

11

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

12

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

13

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

14

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

15

Guo A (2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

16

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

17

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

18

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

19

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

20

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

21

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

22

Possemato A (2010) CST Curation Set: 9394; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

23

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

24

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

25

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

26

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

27

Stokes M (2008) CST Curation Set: 4388; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

28

Stokes M (2008) CST Curation Set: 4390; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

29

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

30

Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

31

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info